Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Amylyx Pharmaceuticals, Inc. (AMLX : NSDQ)

• Company Description    Amylyx Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It focuses on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc. is based in CAMBRIDGE, Mass. Number of Employees: 123

• Price / Volume Information    Yesterday's Closing Price: $12.31 Daily Weekly Monthly 20 Day Moving Average: 1,593,470 shares Shares Outstanding: 109.82 (millions) Market Capitalization: $1,351.88 (millions) Beta: -0.34 52 Week High: $16.96 52 Week Low: $2.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.68% -15.94% 12 Week 53.88% 47.49% Year To Date 225.66% 184.66%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 43 Thorndike St. - Cambridge,MA 02141 USA ph: 617-682-0917 fax: - investors@amylyx.com http://www.amylyx.com

• General Corporate Information    Officers Joshua B. Cohen - Co-Chief Executive Officer James M. Frates - Chief Financial Officer Paul Fonteyne - Director Daphne Quimi - Director Karen Firestone - Director Peer Information Amylyx Pharmaceuticals, Inc. (GSAC) Amylyx Pharmaceuticals, Inc. (CASI) Amylyx Pharmaceuticals, Inc. (ALCD.) Amylyx Pharmaceuticals, Inc. (OMNN) Amylyx Pharmaceuticals, Inc. (CGPI.) Amylyx Pharmaceuticals, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 03237H101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/03/26 Share - Related Items Shares Outstanding: 109.82 Most Recent Split Date: (:1) Beta: -0.34 Market Capitalization: $1,351.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.39 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 58.33% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.07 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 30.19% vs. Previous Quarter: 19.57% Sales Growth vs. Year Ago Period: -99.59% vs. Previous Quarter: -% ROE 09/30/25 - -68.95 06/30/25 - -82.48 03/31/25 - -77.21 ROA 09/30/25 - -61.52 06/30/25 - -70.15 03/31/25 - -63.84 Current Ratio 09/30/25 - 13.70 06/30/25 - 8.72 03/31/25 - 12.05 Quick Ratio 09/30/25 - 13.70 06/30/25 - 8.72 03/31/25 - 12.05 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - 3.02 06/30/25 - 1.88 03/31/25 - 2.26 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©